NovaBay's skin fungus drug shows strong animal data
NovaBay Pharmaceuticals of the USA has reported strong preclinical animal data showing that NVC-422, the company's lead Aganocide compound, was effective in treating skin fungus infections.
The study of NVC-422, which is a synthetic bioequivalent form of the most effective and rapidly-acting anti-infective molecules produced by white blood cells, revealed significant clinical and mycological efficacy compared to the untreated control group at all doses evaluated, with the highest clinical and mycological efficacy rates of 36.6% (p <0.0001) and 97.9% (p <0.05), respectively, achieved in the highest dose group.
According to the firm, these data confirm previous preclinical results that showed a high level of activity for high-dose NVC-422 against dermatophytes. The results were presented at the American Academy of Dermatology 67th annual meeting in San Francisco.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze